Dyne Therapeutics (NASDAQ:DYN) Trading 3.9% Higher

Dyne Therapeutics, Inc. (NASDAQ:DYN)’s stock price shot up 3.9% during mid-day trading on Thursday . The company traded as high as $35.30 and last traded at $35.25. 132,541 shares were traded during trading, a decline of 92% from the average session volume of 1,718,124 shares. The stock had previously closed at $33.92.

Analyst Ratings Changes

A number of brokerages recently issued reports on DYN. Oppenheimer reissued an “outperform” rating and set a $47.00 price target on shares of Dyne Therapeutics in a research report on Monday, May 6th. Stifel Nicolaus raised their target price on Dyne Therapeutics from $35.00 to $41.00 and gave the company a “buy” rating in a report on Wednesday, March 6th. Chardan Capital raised their target price on Dyne Therapeutics from $31.00 to $42.00 and gave the company a “buy” rating in a report on Tuesday, May 21st. Jefferies Financial Group raised their target price on Dyne Therapeutics from $36.00 to $42.00 and gave the company a “buy” rating in a report on Monday, May 20th. Finally, Morgan Stanley initiated coverage on Dyne Therapeutics in a research note on Tuesday, April 30th. They issued an “overweight” rating and a $40.00 price target for the company. One research analyst has rated the stock with a sell rating, eight have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, Dyne Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $40.78.

Dyne Therapeutics Trading Down 0.4 %

The company has a 50-day moving average of $30.02 and a 200-day moving average of $24.51.

Dyne Therapeutics (NASDAQ:DYN) last announced its earnings results on Thursday, May 2nd. The company reported ($0.81) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.81). On average, equities research analysts anticipate that Dyne Therapeutics, Inc. will post -3 earnings per share for the current year.

Insider Transactions at Dyne Therapeutics

In other news, SVP Richard William Scalzo sold 2,588 shares of Dyne Therapeutics stock in a transaction dated Thursday, May 16th. The stock was sold at an average price of $28.27, for a total value of $73,162.76. Following the completion of the transaction, the senior vice president now directly owns 116,695 shares of the company’s stock, valued at approximately $3,298,967.65. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In other news, insider Oxana Beskrovnaya sold 2,136 shares of the firm’s stock in a transaction dated Tuesday, June 11th. The stock was sold at an average price of $31.34, for a total value of $66,942.24. Following the completion of the sale, the insider now directly owns 147,511 shares in the company, valued at approximately $4,622,994.74. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, SVP Richard William Scalzo sold 2,588 shares of the firm’s stock in a transaction dated Thursday, May 16th. The shares were sold at an average price of $28.27, for a total value of $73,162.76. Following the completion of the sale, the senior vice president now owns 116,695 shares of the company’s stock, valued at $3,298,967.65. The disclosure for this sale can be found here. In the last ninety days, insiders sold 202,133 shares of company stock valued at $6,500,387. Corporate insiders own 20.77% of the company’s stock.

Institutional Trading of Dyne Therapeutics

Large investors have recently made changes to their positions in the company. Federated Hermes Inc. acquired a new position in Dyne Therapeutics during the 4th quarter valued at about $4,988,000. Rafferty Asset Management LLC boosted its stake in shares of Dyne Therapeutics by 17.7% in the 4th quarter. Rafferty Asset Management LLC now owns 164,041 shares of the company’s stock worth $2,182,000 after buying an additional 24,632 shares during the last quarter. Commodore Capital LP purchased a new position in shares of Dyne Therapeutics in the 4th quarter worth approximately $11,970,000. Acuta Capital Partners LLC raised its holdings in shares of Dyne Therapeutics by 100.7% in the 3rd quarter. Acuta Capital Partners LLC now owns 146,500 shares of the company’s stock worth $1,313,000 after purchasing an additional 73,500 shares during the period. Finally, Octagon Capital Advisors LP raised its holdings in shares of Dyne Therapeutics by 14.4% in the 4th quarter. Octagon Capital Advisors LP now owns 792,945 shares of the company’s stock worth $10,546,000 after purchasing an additional 100,000 shares during the period. 96.68% of the stock is currently owned by institutional investors and hedge funds.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.